1. Smithkline Beecham Corporation (27 from 2,198 patents)

2. Glaxo Group Limited (8 from 1,168 patents)

3. Smithkline Beckman Corporation (8 from 207 patents)

4. Glaxosmithkline Intellectual Property Development Limited (7 from 230 patents)

5. Other (6 from 832,912 patents)

6. Glaxosmithkline LLC (5 from 356 patents)

7. Astex Therapeutics Limited (5 from 123 patents)

8. Nps Pharmaceuticals, Inc. (5 from 93 patents)

9. Nycomed Austria Gmbh (1 from 9 patents)

10. Smithkline Beechman Corporation (1 from 7 patents)

1. 11688017 - Computer system and method for detecting, extracting, weighing, benchmarking, scoring, reporting and capitalizing on complex risks found in buy/sell transactional agreements, financing agreements and research documents

2. 11205233 - Computer system and method for detecting, extracting, weighing, benchmarking, scoring, reporting and capitalizing on complex risks found in buy/sell transactional agreements, financing agreements and research documents

3. 11117905 - Bisaryl heterocycles as NRF2 activators

4. 11078216 - Bisaryl amides as NRF2 activators

5. 10783578 - Computerized systems and methods for detecting, risk scoring and automatically assigning follow-on action codes to resolve violations of representation and warranties found in loan servicing contracts, loan purchase and sale contracts, and loan financing contracts

6. 10604509 - Nrf2 regulators

7. 10485806 - Nrf2 regulators

8. 10364256 - Biaryl pyrazoles as NRF2 regulators

9. 10351530 - Arylcyclohexyl pyrazoles as NRF2 regulators

10. 10272095 - NRF2 regulators

11. 9227914 - Calcilytic compounds

12. 8980950 - Calcilytic compounds

13. 8586631 - Calcilytic compounds

14. 8399517 - Calcilytic compounds

15. 8354416 - 7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase